Literature DB >> 1661450

Studies on the leishmaniases in the Sudan. 2. Clinical and parasitological studies on cutaneous leishmaniasis.

S H el-Safi1, W Peters, B el-Toam, A el-Kadarow, D A Evans.   

Abstract

In the Omdurman Hospital for Tropical Diseases, Sudan, from 6 October to 1 December 1986, 736 patients with cutaneous leishmaniasis (CL) were studied. The duration of the lesions varied from a few days to 4 months, usually (56%) 1-3 months. Multiple lesions ranging from one to 50 (mean = 4) were present in 80% of cases. Ulcerative lesions were found in 44%, nodulo-ulcerative in 31%, nodular in 31% and others, including infiltrated, fungating and warty lesions, in 5% of patients. The lower limbs were involved in 66%, upper limbs in 50%, face in 6%, back in 4%, chest in 2%, abdomen in 1% and buttocks in 0.1%. Lesions were also found on the ear, scalp, genitalia and mucocutaneous junctions. Lymphatic involvement was present in 11% of the patients, secondary infection in 18%, fever in 17%, pain in 38% and itching in 61%; 3% of the patients were diabetics. Features of diffuse cutaneous leishmaniasis were noted in one patient and three cases presented with an 'id' reaction. A slit-skin smear was positive in 88% of the cases. Using thin-layer starch gel electrophoresis, 23 stocks from man and one from Arvicanthis niloticus were identified by the characterization of 12 enzymes as Leishmania major zymodeme LON-1. Various therapeutic regimens are discussed. Only patients with severe lesions (approximately 15%) were given 3 to 4 weeks' treatment with intravenous Pentostam, to which all except 2 responded satisfactorily with minimal side effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661450     DOI: 10.1016/0035-9203(91)90218-n

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Isolation of bacteria causing secondary bacterial infection in the lesions of Cutaneous Leishmaniasis.

Authors:  Hengameh Ziaie; G Sadeghian
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

3.  Distribution frequency of pathogenic bacteria isolated from cutaneus leishmaniasis lesions.

Authors:  Hengameh Ziaei; Giti Sadeghian; S H Hejazi
Journal:  Korean J Parasitol       Date:  2008-09       Impact factor: 1.341

Review 4.  Leishmania infection: painful or painless?

Authors:  Sergio M Borghi; Victor Fattori; Ivete Conchon-Costa; Phileno Pinge-Filho; Wander R Pavanelli; Waldiceu A Verri
Journal:  Parasitol Res       Date:  2016-12-09       Impact factor: 2.289

5.  Antigen-presenting cells in human cutaneous leishmaniasis due to Leishmania major.

Authors:  A M ElHassan; A Gaafar; T G Theander
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

6.  Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections.

Authors:  A Gaafar; A Kharazmi; A Ismail; M Kemp; A Hey; C B Christensen; M Dafalla; A Y el Kadaro; A M el Hassan; T G Theander
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

7.  Uncharted territory of the epidemiological burden of cutaneous leishmaniasis in sub-Saharan Africa-A systematic review.

Authors:  Temmy Sunyoto; Kristien Verdonck; Sayda El Safi; Julien Potet; Albert Picado; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2018-10-25

8.  Epidemiological and molecular investigation of resurgent cutaneous leishmaniasis in Sudan.

Authors:  Sarah Collis; Sayda El-Safi; Atia A Atia; Tapan Bhattacharyya; Awad Hammad; Margriet Den Boer; Hai Le; James A Whitworth; Michael A Miles
Journal:  Int J Infect Dis       Date:  2019-08-20       Impact factor: 3.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.